case_images: PMC6275313_01
case_images: (A,B) represent PET-CT images of two different pelvic metastases in the radiation field. Upper panel of (A,B): PET/CT on 30Sep2015, before Promitil with radiotherapy. Lower panel of (A,B): PET/CT on 28Dec2016, 15 months after Promitil with radiotherapy. Axial CT (left panel), FDG PET (middle panel) and fused FDG PET/CT (right panel) images of two metastatic lesions. The intense pathological uptake in a left nodule anteriorly to the rectal anastomosis (A, arrows) and in a right para-rectal nodule (B, arrows) has completely resolved with therapy on both PET and CT, along a prolonged follow-up (A,B, lower panel). Note post radiation rectal wall thickening on post-therapy CT images.
case_images: fonc-08-00544-g0001.jpg
case_images: PMC6275313_01_fonc-08-00544-g0001.jpg
case_images: F1
case_images: The treatment resulted in significant pain relief, complete regression of affected nodes by FDG PET-CT (Figure 1) and a significant and durable drop of tumor marker levels (Figure 2).
case_images: Tumor marker response to Promitil with radiotherapy. Same patient as in Figure 1. Note the sustained decrease of CEA and Ca19-9 levels after chemo-radiotherapy.
case_images: fonc-08-00544-g0002.jpg
case_images: PMC6275313_01_fonc-08-00544-g0002.jpg
case_images: F2
case_images: The treatment resulted in significant pain relief, complete regression of affected nodes by FDG PET-CT (Figure 1) and a significant and durable drop of tumor marker levels (Figure 2).
case_images: PMC6275313_02
case_images: Axial CT (left panel), FDG PET (middle panel) and fused FDG PET/CT (right panel) images before Promitil with radiotherapy (A, 07Apr2016), 3 months after Promitil with radiotherapy (B, 04July2016), and on a recent re-evaluation 22 months later (C, 19Feb2018). Initial pre-therapy intense pathological uptake in two adjacent porto-caval lymph nodes (arrows) resolved after therapy, with significant interval reduction in lymph nodes dimensions.
case_images: fonc-08-00544-g0003.jpg
case_images: PMC6275313_02_fonc-08-00544-g0003.jpg
case_images: F3
case_images: He responded with a metabolic CR of the porto-caval hilar lymphadenopathy by FDG PET/CT (Figure 3).